Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients (NCT06807593)

🧪 Interventions in This Study

• Ustekinumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• The University of Texas M. D. Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (281) 221-9138

Email: ywang59@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cancer

• Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Aurora, Colorado
• Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
• An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
• Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
• Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California

Explore by condition: All Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.